Retatrutide FDA approval status

Where retatrutide actually is - August 2026

Retatrutide (LY3437943) is Eli Lilly's investigational GIP/GLP-1/glucagon triple receptor agonist. In the Phase 2 trial published in the New England Journal of Medicine, participants on the highest dose lost a mean of about 24% of body weight at 48 weeks - the largest reduction reported for any anti-obesity medication in a Phase 2 setting. That result is why search interest exploded, and why a gray market appeared years before approval.

The pivotal Phase 3 trial has now read out: TRIUMPH-1 (NCT05929066, 2,339 participants) met its primary and key secondary endpoints at every dose tested, with mean weight loss of 28.3% at 12 mg and 45.3% of participants losing 30% or more: results in bariatric-surgery territory. A positive pivotal readout starts the regulatory clock: Lilly has signaled a submission around early 2027, which would place a realistic FDA decision in 2027-2028 under standard review. No submission, no PDUFA date, and no accelerated pathway has been publicly confirmed as of August 2026.

New: a pre-approval expanded access program is open

In June 2026, Lilly quietly opened a pre-approval expanded access program for retatrutide (NCT07629401, status “Available”, last updated August 6, 2026). It is a single-patient (“compassionate use”) pathway: a physician applies to Lilly for one named adult with severe, refractory obesity - a BMI of 35 or higher despite full-dose treatment with the best approved therapy, plus at least two serious or life-threatening obesity-related complications - who cannot join an ongoing trial.

Two honest readings. Narrowly, this is a compassionate-use mechanism, not an availability announcement: it will cover very few patients, by physician application only. As a signal, though, drugmakers typically open pre-approval expanded access when a filing is close enough that the ethics of refusing access stop being defensible. Combined with the TRIUMPH-1 readout, this is the strongest concrete sign yet that Lilly is preparing its submission. It changes nothing about the market: retatrutide remains unapproved, and nothing sold online became legal.

What the FDA has said

• Retatrutide is not approved for any indication.
• It cannot currently be legally compounded - unlike semaglutide and tirzepatide during their official shortage periods, there is no shortage-based pathway, because there is no approved product to be in shortage.
• The agency has warned about unapproved GLP-1 products sold online, including products marketed as “research use only” retatrutide, citing unknown purity, identity, and dosing risks.

Translation: anything sold as retatrutide today - telehealth, med-spa, or “research chemical” website - is either unlawful, unverifiable, or both.

Signals we watch for the next update

• Expanded access opening - fired, June-August 2026 (section above).
• TRIUMPH-1 registry status - fired: marked Completed on ClinicalTrials.gov, August 21, 2026. The pivotal trial is formally done; with TRIUMPH-1 and two sister Phase 3 trials (T2D, cardiovascular) now completed, the submission package is assembling.
• TRIUMPH-1 full results publication (topline is out; the paper and safety detail come next).
• Lilly's submission announcement - the real starting gun.
• Any FDA advisory-committee scheduling.
• New FDA warning letters naming sellers.

What approval day will change

On approval, retatrutide becomes a branded prescription product with a list price, insurance criteria, and a legitimate telehealth prescribing route - the same arc semaglutide and tirzepatide followed. Until then, the only legal routes are a clinical trial or the physician-initiated expanded access program described above.

Doing dose math for a trial protocol or preparing for the approved product? The retatrutide calculator handles mg-to-units conversion - math only.

Changelog

Sources: NEJM Phase 2 publication (Jastreboff et al.), Eli Lilly investor communications, FDA drug-alert statements on unapproved GLP-1 products. This page reports regulatory facts and is not medical advice.